Back to Journals » Psoriasis: Targets and Therapy » Volume 9

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives

Authors Ly K, Beck KM, Smith MP, Orbai AM, Liao W

Received 4 April 2019

Accepted for publication 23 August 2019

Published 28 August 2019 Volume 2019:9 Pages 97—107

DOI https://doi.org/10.2147/PTT.S161453

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Professor Uwe Wollina


Karen Ly,1 Kristen M Beck,1 Mary P Smith,1 Ana-Maria Orbai,2 Wilson Liao1

1Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USA

Correspondence: Kristen M Beck
Department of Dermatology, University of California San Francisco, 515 Spruce Street, San Francisco, CA 94118, USA
Tel +1 415 476 4701
Fax +1 415 502 4126
Email kristenbeckmd@gmail.com

Abstract: Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It has demonstrated comparable efficacy to biologics, is effective in the management of treatment resistant disease, and is reported to improve enthesitis, dactylitis, and radiographic progression. Tofacitinib is also associated with an increased risk of serious infections, malignancy, and laboratory abnormalities. There is currently a large armamentarium of therapies for psoriatic arthritis, and choosing among treatments can be challenging. Due to this wide selection, a thorough assessment of psoriatic disease phenotype, patient preference, disease presentation, and comorbidities is critical. This review addresses key considerations in patient selection for the treatment of PsA with tofacitinib.

Keywords: tofacitinib, psoriatic arthritis, janus kinase, kinase inhibitors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]